Someone I rely on for advice suggested to me that AKAM was a very weak stock technically. Thinking there may be downside risk as opposed to upside surprise. I was forced to conserve capital. You may be pleasantly rewarded. I am told the stock is technically busted. . My friend referred to the moving averages and very negative money flow. There were 3 upgrades last week and the damn stock couldn't get back to 36.
no one likes to take a loss and admit they were wrong about a stock but I have sold this stock and bought BMY which will go UP and pay a dividend. Added a few bucks to INTC and SNDK. I am conceerned that if market corrects that AKAM may be headed to 29 bucks. Bandwidth prices are going down. Short interest on this stock going up for a reason. Can't afford the risk any more.
I was a believer in DCTH. Most of these biotechs eventually crash and burn. Woulda been great buy at a buck.... for a trade...Phase 1 not in human trials is probably 1000 to 1 shot!
Where is the sales data? I am trying to understand this but don't see any sales data to support your claim
This is not going to be a one day trade. QCOR look at where it was when Citron first did their research. Z got me before but it has topped so get out while you can.
Sentiment: Strong Sell
YE12 PX-866: Complete enrollment in Phase II CRC trial (w/ Erbitux)
1Q13 Stimuvax: Phase III data as a maintenance treatment in Stage
1Q13 PX-866: Phase II NSCLC data (w/ Taxotere)
1H13 PX-866: Complete enrollment in SSCHN Phase II trial (w/
2H13 PX-866: Phase II CRC data (w/ Erbitux
YE2013 Stimuvax: Possible BLA submission for NSCLC maintenance
4Q14 Stimuvax: Possible U.S. approval in NSCLC maintenance
1Q15 Stimuvax: Possible EU approval in NSCLC maintenance
Late 2015 Stimuvax: Phase III INSPIRE trial data in NSCLC maintenance
Source: Company reports, Bloomberg, and Stifel Nicolaus
Initiating Coverage of Oncothyreon with a Buy Rating and $10 Target Price
Stimuvax success would provide significant upside potential while emerging pipeline gives downside protection
Lead compound Stimuvax is approaching completion in a large Phase III
study for non-small cell lung cancer (NSCLC), with final data by partner
Merck KGaA likely in 1Q13. We anticipate this will be a classic biotech binary
event, with potential to transform treatment of disease if results are positive, and
potential for stock price volatility from now through the data read-out. The stock
was down 40% upon disclosure that the trial did not meet the interim analysis in
We rate the probability of success for Stimuvax in NSCLC at around 50%, but
view the risk/reward scenario as very compelling given the current valuation
and downside protection offered by the company’s pipeline. Upon Stimuvax
success, we expect ONTY to trade to $15-20/share,
Zillow is a thorn to Realtors. The valuations shown are way too high. which makes it difficult to convince clients to list at reasonable price.
Stock has an 82 PE which is ridiculous.
Fair value is about 17
I think American Greetings should be investigated for fraudulent business practices based on my personal experiences. About a year ago I had an online subscription at a nominal price and I used the internet cards to stay in contact with family members and to remember important occasions.
When I received a reminder of a nephew's birthday in February, I decided to sign up for a month so that I could send out a few cards.
I didn't read the "fine print" and did not realize that I was getting billed by American Greetings every month. I have a big credit card bill and the 3.98 charge was missed by me until this month when I happened to notice it. I can afford the 28 bucks I paid for cards I am not using but I am angry as hell because I feel like I was duped by AM.
I didn't see the "fine print" that this would be a recurring charge and I am sure others' have had this experience.
I have tried some of their products. Prefer Loreal, Estee Lauder. They have one product that is supposed to keep insects off of you that isn't bad.
Otherwise I think it is "Cheap Goop...better stuff in Department stores.
There is no reason to buy JCP based on anything but Ackman and if the economy was better it could be a good bet.
The new strategy in place seems to have some merit but I personally think it is too little too late.
Ackman has made big bets before and been wrong.
JCP is not AAPL.
They are giving $JCP a chance to prove themselves but after September numbers should get dismal
I just shorted 400 shares will add
This stock is garbage and will soon reward shorts
Love to see it totally collapse buut market needs to collapse as well